Sunshine Biopharma Inc
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor … Read more
Sunshine Biopharma Inc (SBFM) - Total Liabilities
Latest total liabilities as of September 2025: $7.29 Million USD
Based on the latest financial reports, Sunshine Biopharma Inc (SBFM) has total liabilities worth $7.29 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sunshine Biopharma Inc - Total Liabilities Trend (2007–2024)
This chart illustrates how Sunshine Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sunshine Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of Sunshine Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hexagon Resources Ltd
AU:HXG
|
Australia | AU$2.76 Million |
|
DILLARDS-A
BE:DL7A
|
Germany | €1.71 Billion |
|
Dien Quang JSC
VN:DQC
|
Vietnam | ₫447.81 Billion |
|
CV Sciences Inc
OTCQB:CVSI
|
USA | $5.46 Million |
|
SA Corporate Real Estate Fund Managers Ltd
JSE:SAC
|
South Africa | ZAC8.91 Billion |
|
Peregrine Gold Ltd
AU:PGD
|
Australia | AU$1.08 Million |
|
Silla Sg Co. Ltd
KQ:025870
|
Korea | ₩33.67 Billion |
Liability Composition Analysis (2007–2024)
This chart breaks down Sunshine Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sunshine Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sunshine Biopharma Inc (2007–2024)
The table below shows the annual total liabilities of Sunshine Biopharma Inc from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $7.06 Million | +14.99% |
| 2023-12-31 | $6.14 Million | -22.46% |
| 2022-12-31 | $7.92 Million | +297.62% |
| 2021-12-31 | $1.99 Million | -0.45% |
| 2020-12-31 | $2.00 Million | +139.98% |
| 2019-12-31 | $833.53K | -30.67% |
| 2018-12-31 | $1.20 Million | +44.71% |
| 2017-12-31 | $830.85K | +203.11% |
| 2016-12-31 | $274.10K | -78.42% |
| 2015-12-31 | $1.27 Million | +139.23% |
| 2014-12-31 | $531.00K | +1263.29% |
| 2013-12-31 | $38.95K | -39.49% |
| 2012-12-31 | $64.37K | +1774.40% |
| 2011-12-31 | $3.43K | -69.89% |
| 2010-12-31 | $11.40K | -20.33% |
| 2009-12-31 | $14.31K | -37.05% |
| 2008-12-31 | $22.74K | +1415.93% |
| 2007-12-31 | $1.50K | -- |